Inventing & translating technologies for therapies. ML AI ‘omics & comp biology. Molecular glue for targeted protein degraders. @MonteRosaTx Tweets my own
Mainz, Germany
Joined November 2010
- Tweets485
- Following1.3K
- Followers784
- Likes2.8K
John Castle retweeted
𝐅𝐫𝐨𝐦 𝐁𝐚𝐬𝐞𝐥: @MonteRosaTx announced data for MRT-8102, its NEK7-directed molecular glue degrader, showing positive impact on biomarkers linked to atherosclerotic cardiovascular disease. $GLUE
Full video: biotechtv.com/post/monte-ros…
What stands out in the GFORCE-1 results is the breadth of the response across multiple pathogenic pathways that can lead to atherosclerosis and thrombogenesis. These data give us much to build on as we advance MRT-8102.
Today, we announced positive results from our Phase 1 study of MRT-8102, a NEK7-directed molecular glue degrader being developed for NEK7/NLRP3-driven diseases, supporting our plans for Phase 2 studies.
bit.ly/4z8xv7g
John Castle retweeted
Today, we announced positive results from our Phase 1 study of MRT-8102, a NEK7-directed molecular glue degrader being developed for NEK7/NLRP3-driven diseases, supporting our plans for Phase 2 studies.
bit.ly/4z8xv7g
John Castle retweeted
Today, we report financial results and business highlights for the second quarter 2026.
CEO @markus_warmuth shares his perspective on our second quarter performance, recent milestones, and the continued momentum across our pipeline.
Read more: bit.ly/4hcjyj0
John Castle retweeted
Today we're unveiling Dimension III: a $800M fund to partner with the leading entrepreneurs across the frontiers of compute (silicon through infrastructure) & science (biotech through physics).
To our founders, past, present, and future: now is your time. LFG!
John Castle retweeted
Great interview with $GLUE CEO @markus_warmuth:
"I'm looking forward for the world to learn more about how Novartis thinks about the program and how broadly their hoping to develop MRT-6160." shows.acast.com/behind-the-b…
John Castle retweeted
We’re turning scientific insight into meaningful progress for heart health – advancing a new way to treat inflammation in ASCVD by targeting the NLRP3/NEK7 pathway upstream. Our NEK7-directed molecular glue degrader, MRT-8102, is designed to stop NLRP3 activation at the source.
John Castle retweeted
Today, we announced updated, positive clinical data from an ongoing Phase 1/2 clinical study evaluating MRT-2359 in combination with enzalutamide in heavily pretreated patients with metastatic castration-resistant prostate cancer (mCRPC). bit.ly/4u87raO
John Castle retweeted
It’s not “just” cholesterol. The role of inflammation in atherosclerotic cardiovascular disease (ASCVD) is gaining increased attention.
John Castle retweeted
CMO, Filip Janku, comments on the future clinical plans for MRT-8102 based on the highly encouraging data we have observed so far in our ongoing Phase 1 study.
Read the full data release here:
bit.ly/4pxGtWz
John Castle retweeted
congrats @MonteRosaTx ($GLUE) on this morning's stunning data from MRT-8102, showing potent NEK7 degradation and potential best in class removal of hsCRP in a daily oral format. this is a potential game changer for ASCVD
Dimension has co-led a $100M financing into @MonteRosaTx. Thrilled to support @markus_warmuth and the entire team at the cutting edges of geometric deep learning, next gen proteomics, and molecular glue degraders.
John Castle retweeted
Today, we reported positive interim data from an ongoing Phase 1 study of MRT-8102. We believe these data support the potential of MRT-8102 to be an oral best-in-class therapeutic among agents targeting the NRLP3/IL-1/IL-6 pathway. bit.ly/4pxGtWz
Great news today from Monte Rosa. Kudos to the team and a shout out to our scientists who discovered this promising program. Degrading proteins, making medicines.
John Castle retweeted
Today, we announced positive interim data from an ongoing Phase 1 clinical study evaluating MRT-8102, a NEK7-directed MGD being developed for the treatment of inflammatory conditions driven by the NLRP3 inflammasome, IL-1, and IL-6.
Pleasure working with a tremendous team to transform degraders into medicines.
Our invited review in @TrendsinBiotech is now out in print. The piece explores how machine learning can predict de novo protein–protein interactions, including those induced by our molecular glues.
Kudos to the team for their leadership in this field: bit.ly/3Y503xT
John Castle retweeted
Through proteomic profiling of our proprietary compound library, our team identified a selective, fast, and potent molecular glue degrader that induces cereblon degradation via a novel mechanism.
Read the full paper in @NatureComms: rdcu.be/eQKQk
John Castle retweeted
Today we announced our second collaboration with @Novartis to develop novel degraders for immune-mediated diseases. Given the strong progress we’ve made on our collaboration advancing VAV1 degraders, we’re thrilled to be collaborating with them again: bit.ly/4piSOyN
John Castle retweeted
Thanks to Alex Eccleston of Nature Reviews Drug Discovery for a very nice summary of our recent Science Magazine publication. If you don’t have time to read the full paper, make the time! Or read this summary, which provides a great overview. nature.com/articles/d41573-0…
John Castle retweeted
𝐁𝐞𝐡𝐢𝐧𝐝 𝐭𝐡𝐞 𝐒𝐜𝐞𝐧𝐞𝐬: BiotechTV visited @MonteRosaTx in Boston, MA yesterday and learned about the work they are doing on molecular glue degraders. Scientist Katherine Jones showed us some of the equipment that makes it happen.
John Castle retweeted
𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: @MonteRosaTx's CEO @markus_warmuth updates us on the company's progress in developing molecular glue degraders. $GLUE
Full video: biotechtv.com/post/monte-ros…